Skincare Ingredient Science and Derm Studies — 2026-09-15
The skincare industry is witnessing a significant shift in anti-aging mechanisms, with Korean brand TOUN28 launching "Blue Peptides" as a successor to PDRN and retinol. Simultaneously, the U.S. market is actively integrating Bemotrizinol, the first new FDA-approved sunscreen filter in decades, into commercial products as of August 2026.
Skincare Ingredient Science and Derm Studies — 2026-09-15
Top developments
TOUN28 Launches "Blue Peptides" as Next-Gen Anti-Aging
On September 11, 2026, Korean beauty brand TOUN28 unveiled its new "Blue Peptide" ingredient at the "2026 TOUN28 2.0 UNPACK : THE FIRST BLUE" event in Seoul. The company positions this new peptide complex as a successor to PDRN and retinol, shifting the anti-aging paradigm from simple ingredient infusion to inducing the skin’s inherent regenerative activity. This launch highlights a growing trend in K-beauty where "induction" of skin health is replacing traditional "delivery" methods for active ingredients.
WJ Cosmetics Publishes Post-Laser Care Study
Research by WJ Cosmetics, a derma-cosmetic brand affiliated with Wonjin Plastic Surgery Hospital, was published in the July 2026 issue of Archives of Aesthetic Plastic Surgery. The study details a protocol for using their products for skin calming and adjunctive therapy following laser procedures, emphasizing the role of specific ingredients in post-procedure recovery. This publication underscores the increasing integration of clinical dermatology findings into consumer-facing skincare formulations.
Bemotrizinol Products Hit US Shelves
As of early September 2026, new sunscreen products containing Bemotrizinol are appearing on U.S. shelves, marking the practical implementation of the FDA's June 2026 approval. The ingredient, permitted at concentrations up to 6%, is now available through brands like Ultra Violette and via supply chains from dsm-firmenich (Parsol Shield). This development closes a 27-year gap where the U.S. lagged behind Europe and Asia in adopting this broad-spectrum UV filter.
Local view
Korean media outlets are heavily focusing on the strategic pivot of major conglomerates toward global expansion of derma-cosmetics. Youth Daily reported that Amorepacific is accelerating its push for global expansion in derma-beauty, clinical skincare, and haircare to meet its target of 15 trillion won in revenue by 2035. Additionally, Bio Times highlights the market sentiment that consumers are moving away from "ingredient worship" toward understanding mechanism-based efficacy, with "Blue Peptides" cited as a prime example of this evolution.
Context & numbers
- Amorepacific Target: The Korean beauty giant aims for 15 trillion won (~$10.8 billion USD) in annual revenue by 2035, driven by international growth in clinical skincare categories.
- Bemotrizinol Concentration Limit: The FDA has finalized the monograph allowing Bemotrizinol in OTC sunscreens at concentrations up to 6% for adults and children aged 6 months and older.
- Effective Date: The final order for Bemotrizinol use became effective on August 9, 2026, enabling immediate product formulation and sales.
On the radar
- BEYOND BEAUTY TOKYO 2026: The upcoming beauty trade show in Tokyo (September 30 – October 2) will feature presentations on next-generation cosmetic ingredients, potentially revealing further advancements in peptide technology.
- Dermatology Times Journal Digest: Recent digests have highlighted studies on AGA (androgenetic alopecia) cardiovascular risks and narrowband-UVB phototherapy for urticaria pigmentosa, indicating a broader clinical focus beyond topical anti-aging.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
